September 11th 2024
Wendie Berg. MD, PhD, explains new breast density reporting standards, cancer risks, and the importance of supplemental imaging for dense breast tissue.
Patient, Provider, and Caregiver Connection™: Exploring Unmet Needs In Postpartum Depression – Making the Case for Early Detection and Novel Treatments
View More
Identifying Health Care Inequities in Screening, Diagnosis, and Trial Access for Breast Cancer Care: Taking Action With Evidence-Based Solutions
View More
16th Annual International Symposium on Ovarian Cancer and Other Gynecologic Malignancies™
May 3, 2025
View More
Addressing Healthcare Inequities: Tailoring Cancer Screening Plans to Address Inequities in Care
View More
Clinical Consultations™: Guiding Patients with Genital Psoriasis Toward Relief Through a Multidisciplinary Approach
View More
Burst CME™: The Patient Journey – Unmet Needs From Diagnosis Through Management of Migraine
View More
Burst CME™: Optimizing Migraine Management – Addressing Unmet Needs, Individualizing Care for Diverse Populations, and Utilizing CGRP Targeted Agents
View More
Burst CME™: Optimizing the Use of CGRP Targeted Agents for the Treatment of Migraine
View More
Burst CME™: Setting the Stage – Individualizing Migraine Care for Diverse Populations Across Care Settings
View More
‘REEL’ Time Patient Counseling™: Fostering Effective Conversations in Practice to Create a Visible Impact for Patients Living with Genital Psoriasis
View More
Navigating Low-Grade Serous Ovarian Cancer – Enhancing Diagnosis, Sequencing Therapy, and Contextualizing Novel Advances
View More
Burst CME™: Implementing Appropriate Recognition and Diagnosis of Low-Grade Serous Ovarian Cancer
View More
Burst CME™: Stratifying Therapy Sequencing for LGSOC and Evaluating the Unmet Needs of the Standard of Care
View More
Burst CME™: Understanding Novel Advances in LGSOC—A Focus on New Mechanisms of Action and Clinical Trials
View More
Cases and Conversations™: Navigating the Complexities of Managing Myasthenia Gravis in Pediatric and Pregnant Patient Populations
View More
Exogenous hormones and patients at increased risk for breast cancer
October 17th 2023This lecture, presented by Holly J. Pederson, MD, at The Menopause Society 2023 Annual Meeting, looked at combined oral contraceptives in BRCA carriers and other high-risk patients, and hormone therapy in postmenopausal gene carriers as well as other high-risk women.
Read More
Hormone replacement therapy does not increase breast cancer recurrence, mortality in survivors
July 20th 2022An analysis of data from more than 8400 postmenopausal women with a history of early-stage nonmetastatic, ER-positive breast cancer suggests there was no increase in risk of breast cancer recurrence or mortality observed with use of vaginal estrogen therapy or menopausal hormone therapy.
Read More
Addressing inequities in cancer care starts with awareness
March 21st 2022Alexander B. Olawaiye, MD, discusses how social and biological determinants can affect care outcomes across cancer subtypes and what steps community and academic oncologists can take to ensure these disparities are recognized.
Read More
Breast cancer diagnosis during and before pandemic
February 23rd 2022A quality improvement study in JAMA Network Open has found that a significantly lower percentage of patients with breast cancer presented with stage I disease before the COVID-19 pandemic, in 2019, compared to after the start of the pandemic, in 2020.
Read More
Trastuzumab deruxtecan significantly improves PFS, OS in HER2-low metastatic breast cancer
February 22nd 2022Trastuzumab deruxtecan resulted in a statistically significant improvement in progression-free survival and overall survival compared with physician’s choice of chemotherapy in patients with HER2-low unresectable and/or metastatic breast cancer, irrespective of hormone receptor status, meeting the primary and secondary end points of the phase 3 DESTINY-Breast 04 trial.
Read More
Premenopausal ER+ breast cancer recurrence reduced significantly with aromatase inhibitors
December 22nd 2021Compared with tamoxifen, aromatase inhibitors were revealed to be more effective in reducing the rate of recurrence in ER+ breast cancer among premenopausal women receiving ovarian suppression.
Read More
Using a biomarker-driven approach in TNBC
December 21st 2021In using the biomarker approach to the treatment of triple-negative breast cancer, the challenge for the clinician is prioritizing the available treatment options based on the National Comprehensive Cancer Network guidelines for breast cancer, which focus on active agents, preferred single-agent chemotherapy approaches, and doublet options for certain patients at high risk.
Read More
Certain postmenopausal patients with breast cancer can avoid chemotherapy, study shows
December 13th 2021Certain post-menopausal women with HR-positive, HER2-negative breast cancer may be able to only undergo endocrine therapy after surgery – sparing themselves from the chemotherapy side effects.
Read More
The addition of palbociclib to endocrine therapy was not associated with preventing disease recurrence in patients with hormone receptor (HR)–positive, human epidermal growth factor receptor 2 (HER2)–negative early breast cancer, according to final results of the phase 3 PALLAS trial.
Read More
Novel drug has potential to ‘become new standard of care’ in advanced, ER-positive breast cancer
December 10th 2021The study results — which were presented during the 2021 San Antonio Breast Cancer Symposium — indicated that elacestrant, a selective estrogen receptor degrader (SERD), led to a 30% reduction in the risk of disease progression or death compared with standard of care in the study population.
Read More
FDA grants olaparib priority review in BRCA-mutated HER2-negative high-risk early breast cancer
December 1st 2021Olaparib, which was granted priority review by the FDA, has been shown to improve invasive disease-free survival for patients with BRCA-mutated HER2-negative high-risk early breast cancer.
Read More
Lack of health insurance directly reduces cancer screening rates, most recent and long-term
November 8th 2021Disparities across the globe continue to surface as we approach year 2 of the COVID-19 pandemic, especially in health care. As one considers its implications, a research team from the American Cancer Society investigated its potential impact on early cancer detection.
Read More
Dynamic treatment for early-stage triple-negative breast cancer
November 2nd 2021Standard chemotherapy has historically been the mainstay of treatment for patients with diagnoses of early-stage TNBC, but there remains an unmet need to identify novel therapies that improve outcomes and, equally important, to discern which patients may benefit from a given treatment.
Read More
CoopERA Results Show Benefits of Giredestrant in ER+/HER2– Early Breast Cancer
October 29th 2021Sara Hurvitz, MD, discusses the coopERA study and how these data, along with findings from other clinical trials, could lead to significant changes in treatment for patients with ER-positive/HER2-negative breast cancer.
Read More